

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **March, 2014**

Commission File Number **001-36187**

**EVOGENE LTD.**

(Translation of Registrant's Name into English)

**13 Gad Feinstein Street  
Park Rehovot P.O.B 2100  
Rehovot 7612002 Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_

---

## CONTENTS

On March 11, 2014, Evogene Ltd., or the Company, held a Special General Meeting of Shareholders, or the Meeting, at its principal executive offices in Rehovot, Israel. At the Meeting, at which a quorum was present, each proposal on the agenda was duly approved. A description of the proposals can be found in the Company's proxy statement with respect to the Meeting, which was attached as Exhibit 99.1 to the Company's Report of Foreign Private Issuer, furnished to the Securities and Exchange Commission on February 10, 2014.

A notice announcing the results of the Meeting is appended to this report as Exhibit 99.1.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.  
(Registrant)

By: /s/ Sigal Fattal

\_\_\_\_\_  
Sigal Fattal  
Chief Financial Officer

Date: March 12, 2014

EXHIBIT INDEX

<u>EXHIBIT NO.</u>	<u>DESCRIPTION</u>
99.1.	A notice announcing Results of Special General Meeting of Shareholders

**Notice of Results of Special General Meeting of Shareholders**

Evogene Ltd., or the Company, announced today that all of the proposals submitted for shareholder approval at its Special General Meeting of Shareholders, held on March 11, 2014 in Rehovot, Israel were duly approved. At the meeting, shareholders of the Company approved each of the following by the requisite majorities under the Company's articles of association and the Israeli Companies Law, 5799-1999:

- (i)(a) The election of Mr. Akiva Mozes as a director of the Company for a one year term.
- (i)(b) The reelection of Mr. Ziv Kop as a director of the Company for a one year term.
- (ii) A Compensation Policy for the office holders of the Company, in accordance with the requirements of the Israeli Companies Law.
- (iii)(a) An initial grant of options, and subsequent annual grants of options, to Mr. Akiva Mozes in accordance with the grant mechanism described in the Compensation Policy, subject to his continued service on the Company's Board of Directors.
- (iii)(b) An initial grant of options, and subsequent annual grants of options, to Mr. Ziv Kop in accordance with the grant mechanism described in the Compensation Policy, subject to his continued service on the Company's Board of Directors.
- (iv) Payment of a one-time cash bonus to Mr. Ofer Haviv, the Company's President and Chief Executive Officer, in respect of his role in the Company's successful consummation of its recent initial public offering in the United States.

March 12, 2014

---

---